On 5 February, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published a Nanomedicine Decision Tree—a structured tool designed to guide manufacturers, developers, and regulatory professionals in determining the appropriate regulatory pathway for nanomedicines.
This decision tree aims to support researchers and developers in navigating the application of various guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and European regulatory agencies. While not exhaustive, it serves as a valuable resource for aligning nanomedicine development with existing regulatory frameworks. For more details, see www.medboard.com.
💡 Navigating regulatory pathways for nanomedicines? Our experts at EUMEDIQ can support you with tailored guidance on MHRA, EU, and global regulations. Get in touch to discuss your needs: info@eumediq.eu